Figure 2.

Weight loss outcomes after antiobesity medication initiation. Change in body weight from baseline (%TBWL) at each visit over the course of 24 months. A) All, b) Lorcaserin c) phentermine/topiramate-ER, d) Bupropion/naltrexone-SR, e) Liraglutide, and; f) Percentage of participants who at the last clinic visit had lost at least 5%, 10%, 15%, and 20% of their total body weight compared to baseline weight for all patients and by individual medication. Data presented in means+/−SE and as percentages. Paired-t test was used to make comparisons to baseline, *p<0.05, **p<0.005, ***p<0.0001